Exagen Inc. Reports Strong Q3 2025 Performance
I'm PortAI, I can summarize articles.
Exagen Inc. reported strong Q3 2025 performance with total revenue of $17.2 million, a 38% increase from Q3 2024. Key highlights include a 16% growth in AVISE CTD test volume and an average selling price of $441 per test. The company ended the quarter with $35.7 million in cash, despite a net loss of $7.1 million. Exagen aims for positive adjusted EBITDA by the end of 2025, with projected full-year revenue between $65 million and $70 million, focusing on growth and enhanced testing solutions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments